SOPHiA GENETICS Announces Instituto Mário Penna as New Customer

May 20, 2024

https://www.prnewswire.com/news-releases/sophia-genetics-announces-instituto-mario-penna-as-new-customer-302149227.html

The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform

BOSTON and ROLLE, Switzerland, May 20, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Instituto Mário Penna is live on the SOPHiA DDM™ Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna will use SOPHiA GENETICS’ technology to advance its testing, research, and advance data-driven diagnoses and treatment decisions for blood-related cancers and disorders.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.